During the last session, Praxis Precision Medicines Inc (NASDAQ:PRAX)’s traded shares were 0.62 million, with the beta value of the company hitting 2.67. At the end of the trading day, the stock’s price was $90.77, reflecting an intraday gain of 4.74% or $4.11. The 52-week high for the PRAX share is $90.33, that puts it up 0.48 from that peak though still a striking 63.63% gain since the share price plummeted to a 52-week low of $33.01. The company’s market capitalization is $1.69B, and the average intraday trading volume over the past 10 days was 0.39 million shares, and the average trade volume was 357.20K shares over the past three months.
Praxis Precision Medicines Inc (PRAX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.27. PRAX has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -2.82.
Praxis Precision Medicines Inc (NASDAQ:PRAX) trade information
Praxis Precision Medicines Inc (PRAX) registered a 4.74% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 4.74% in intraday trading to $90.77, hitting a weekly high. The stock’s 5-day price performance is 4.48%, and it has moved by 30.44% in 30 days. Based on these gigs, the overall price performance for the year is 119.84%. The short interest in Praxis Precision Medicines Inc (NASDAQ:PRAX) is 2.62 million shares and it means that shorts have 7.66 day(s) to cover.
The consensus price target of analysts on Wall Street is $73.61, which implies a decrease of -23.31% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $60.3 and $75.9 respectively. As a result, PRAX is trading at a premium of 16.38% off the target high and 33.57% off the low.
Praxis Precision Medicines Inc (PRAX) estimates and forecasts
In the rating firms’ projections, revenue will decrease -40.50% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 362.25k as predicted by 11 analyst(s). Meanwhile, a consensus of 9 analyst(s) estimates revenue growth to 264.78k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 515k and 431k respectively. In this case, analysts expect current quarter sales to shrink by -29.66% and then drop by -38.57% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -10.28%. While earnings are projected to return 45.51% in 2025, the next five years will return 14.29% per annum.
PRAX Dividends
Praxis Precision Medicines Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Praxis Precision Medicines Inc (NASDAQ:PRAX)’s Major holders
Praxis Precision Medicines Inc insiders own 0.24% of total outstanding shares while institutional holders control 107.35%, with the float percentage being 107.61%. BLACKROCK INC. is the largest shareholder of the company, while 207.0 institutions own stock in it. As of 2024-06-30, the company held over 1.29 million shares (or 6.874% of all shares), a total value of $53.52 million in shares.
The next largest institutional holding, with 1.24 million shares, is of RA CAPITAL MANAGEMENT, L.P.’s that is approximately 6.5638% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $51.1 million.
Also, the Mutual Funds coming in first place with the largest holdings of Praxis Precision Medicines Inc (PRAX) shares are Smallcap World Fund and Vanguard Total Stock Market Index Fund . Data provided on Sep 30, 2024 indicates that Smallcap World Fund owns about 888.06 shares. This amounts to just over 4.76 percent of the company’s overall shares, with a $80.61 million market value. The same data shows that the other fund manager holds slightly less at 541.27, or about 2.90% of the stock, which is worth about $49.13 million.
